@article{3e948149b2e84b46a941093796435497,
title = "Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context",
keywords = "Clinical Trial, Macula, Treatment Medical, Macular Edema/drug therapy, Humans, Endothelial Growth Factors, Ranibizumab/therapeutic use, Diabetes Mellitus, Diabetic Retinopathy/drug therapy",
author = "Do, \{Diana V.\} and Hadi Moini and Wykoff, \{Charles C.\}",
note = "Funding Information: This study was funded by Regeneron Pharmaceuticals, Inc. Funding Information: DVD reports serving as a consultant for Allergan, Asclepix, Boehringer Ingelheim, Clearside, Genentech, Kodiak Sciences and Regeneron Pharmaceuticals, Inc.; and receiving research funding from Asclepix, Boehringer Ingelheim, Genentech and Regeneron Pharmaceuticals, Inc. HM is an employee and shareholder of Regeneron Pharmaceuticals, Inc. CCW reports serving as a consultant for Acucela, Adverum, Aerpio, Alcon, Alimera Sciences, Allergan, Alnylam, Apellis, Arctic Vision, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies, Clearside Biomedical, Corcept Therapeutics, DORC, EyePoint, Genentech, Gyroscope, IVERIC Bio, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Notal Vision, Novartis, OccuRx, ONL Therapeutics, Opthea, Oxurion, Palatin, Polyphotonix, Recens Medical, Regeneron Pharmaceuticals, Inc., RegenXBio, Roche, Santen, Takeda, Thea Open Innovation and Verana Health; receiving grants for research support from Adverum, Aerie Pharmaceuticals, Aldeyra, Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong Biotechnologies, Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, IVERIC Bio, Kodiak Sciences, LMRI, Mylan, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, Recens Medical, Regeneron Pharmaceuticals, Inc., RegenXBio, Roche, Samsung Bioepis, Santen, Senju, Taiwan Liposome Company, and Xbrane BioPharma; and receiving speaker fees for speaker{\textquoteright}s bureau from Regeneron Pharmaceuticals, Inc. ",
year = "2022",
month = aug,
day = "1",
doi = "10.1136/bmjophth-2022-000983",
language = "English (US)",
volume = "7",
journal = "BMJ Open Ophthalmology",
issn = "2397-3269",
publisher = "BMJ Publishing Group",
number = "1",
}